Ultragenyx Pharmaceutical Inc. (RARE) Revenue History
Ultragenyx Pharmaceutical Inc. (RARE) annual revenue history. Get revenue data in Excel with MarketXLS.
Revenue Data
| Period | Revenue (USD) |
|---|---|
| 2016-12-31 | $133.00K |
| 2017-12-31 | $2.61M |
| 2018-12-31 | $51.49M |
| 2019-12-31 | $103.71M |
| 2020-12-31 | $271.03M |
| 2021-12-31 | $351.41M |
| 2022-12-31 | $363.33M |
| 2023-12-31 | $434.25M |
| 2024-12-31 | $560.00M |
| 2025-12-31 | $673.00M |
How RARE compares with sector peers
| Symbol | Company | Revenue (latest fiscal year) |
|---|---|---|
| EBS | Emergent BioSolutions Inc. | $742.90M |
| NEO | NeoGenomics Inc. | $727.33M |
| AMPH | Amphastar Pharmaceuticals Inc. | $719.89M |
| AXSM | Axsome Therapeutics Inc. | $638.50M |
| TGTX | TG Therapeutics Inc. | $616.29M |
These are five companies in the same sector as RARE with a comparable annual revenue. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Ultragenyx Pharmaceutical Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue("RARE", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | RARE | $25.83 | +2.01% | 2.40M |
| 3 | ||||
| 4 | ||||
| 5 |